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experimental models, although their role in the progression of human breast cancer is unclear.
The aim of the current study was to examine the expression pattern of VEGF in serum and tissues
of breast cancer patients, examine the tumor vascular characteristic by counting the blood vessels to
assess microvessles density (MVD) and conduct correlations between the expressions of growth fac-
tor in relation to patient’s clinicopathological data and survival.
Methods: One hundred and twenty untreated patients with breast cancer were included in the study
and followed for 4 years and 30 females with benign breast lesions matched with age and menstrual
state as (control group). In this work we examine serum and tissue expression of VEGF by enzyme
linked immune absorbent assay (ELISA) and immunoperoxidase technique respectively. Microves-
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218 E.M. Ali et al.Results: The mean serum level of VEGF elevated in breast cancer patients before surgery was
signiﬁcantly higher when compared to that in patients with benign breast lesions or in the same
patient after surgery. There was positive correlation between serum and tissue VEGF. Serum
and tissue vascular endothelial growth factor was strongly associated with grade III tumor, large
tumor size, positive lymph node, negative hormone receptor status, +ve HER2 neu and poor sur-
vival, the data of the present study showed signiﬁcant increase in mean serum level of VEGF in
patients with positive vascular invasion P: 0.013.
Conclusion: VEGF appear to play an important role in progression of breast carcinoma and to
have signiﬁcant impact on patient prognosis and can be used to identify a subset of breast cancer
at higher risk for development of recurrence and distant metastasis.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Breast cancer is the commonest form of cancer in women
throughout the world.1
Angiogenesis, the formation of new blood vessels, and
lymphangiogenesis, the formation of new lymphatic, are com-
plex processes in which different signaling systems work to-
gether, one of the most potent and speciﬁc angiogenic factor
is VEGF,2 also known as vascular permeability factor and vas-
culotropin.3 Evidence for the pivotal role of this cytokines in
tumor angiogenesis include the observations of increased
expression in tumor cells of numerous human cancers together
with up regulation of the receptors on the associated endothe-
lial cells and the inhibitory effect of anti-VEGF anti bodies on
tumor growth in vivo.4
Higher VEGF mRNA levels have been found in invasive
breast carcinoma or DCIS, compared with benign or normal
breast tissue.5,6 Assessment of VEGF expression by immuno-
histochemistry or immunoassay of tissue extracts has shown
a signiﬁcant correlation with micro vessels counts or density.7
Since the pivotal ﬁndings in breast cancer of a correlation
between tumor angiogenesis, and metastasis,8 many studies
have conﬁrmed the clinical value of this parameters. High
mean vascular density (MVD) in breast cancer has been re-
ported to be associated with more aggressive tumour behav-
iour and poor survival, intratumoral microvessels density is
now considered as one of the important factors affecting
survival.9,10
Clearly, measurement of circulating soluble marker of angi-
ogenesis would be considerable beneﬁt over more subjective
approaches such as immunohistochemical assessments, or
immunoassays which involve laborious ﬁndings of elevated
VEGF concentrations in patients with cancer, many studies
have reported similar ﬁndings in patients with breast cancer
and many other types of cancer with a higher levels often
found in metastatic disease than in localized disease or in pro-
gressive disease during treatment. Correlations with prognosis
have also been reported for several cancers e.g., ovarian cancer
lung cancer and colon cancer.11–14
The role of VEGF as a potent angiogenic factor in malig-
nant tumors is well established, but it has long been thought
that it had no inﬂuence upon lymphangiogenesis. It has re-
cently been reported, however, that VEGF can induce lym-
phangiogenesis as well as angiogenesis.15
Most of published studies correlate angiogenesis to deter-
mine intra tumoral vascularization (or microvessel density
MVD) by counting microvessels identiﬁed using immunohisto-chemical assays and panendothelial markers such as factor
VIII, CD31, and CD34, with a recent review recommending
procedures that should be followed for the assessment of
MVD in breast cancer.16
The assessment of lymphatic characteristics in malignant
tumors has historically been difﬁcult owing to the lack of avail-
ability of lymphatic-speciﬁc markers. Such markers have re-
cently been characterized and become commercially
available. The count of positively stained vessels per tumor
area, lymph vessels density (LVD), has been used to assess
lymph angiogenic characteristics in tumor specimens.16 High
MVD and LVD in breast cancer have been reported to be
associated with more aggressive tumor behavior and poor out-
come. The aim of the current study was to investigate the
expression pattern of VEGF in serum and tissues, examine
the tumor vascular characteristics by counting the blood ves-
sels to assess MVD, and conduct correlations between expres-
sion of growth factor relation to patient clinicopathological
data and survival.
2. Materials and methods
Between January 2004 and June 2008, 120 non-metastatic pa-
tients with breast cancer presented and treated at the cancer
management and research Department Medical Research
Institute, were included in the study and followed for 4 years.
Eligibility criteria were, histologically proven beast cancer,
adequate haematologic parameters and normal electrocardio-
gram with no history of cardiac problem. All patients under
went therapeutic work up including clinical history, physical
examination, complete haematologic and biochemical studies,
radiological studies including plain X-ray chest, abdominal
ultrasound and CT scan when needed. Another 30 females
with benign breast lesions matched in age and menstrual state
with previous group were included as controls.
2.1. Histopathologic technique
Representative sections of 10% neutral buffered formalin ﬁxed
parafﬁn embedded tissue were stained with H&E stain to ver-
ify, and graded according to bloom and Richardson meth-
od.17–19
2.2. Assessment of MVD
Calculation of the MVD value was calculated without the aid
of any immunomarker, special stain, in order to evaluate its
Table 1 Illustrate the clinicopathological characteristics of
120 patients of non metastatic breast cancer.
Number Percent
Age
<50 78 65.0
>50 42 35.0
Range 24–72
Mean ± SD 46.5±
Menstrual status
Pre menopause 72 60.0
Post menopause 48 40.0
Tumor size
T1 8 6.7
T2 96 80.0
T3 16 13.3
Tumor type
Inﬁltrating duct carcinoma 108 90.0
Inﬁltrating lobular carcinoma 12 10.0
Grade
I 12 10.0
II 68 56.7
III 40 33.3
Vascular invasion
Positive 24 20.0
Negative 96 80.0
Number of L.N.
Negative 40 33.3
Positive 80 66.6
1–3 28 23.3
>3 52 43.3
I 4 3.3
II 84 70.0
III 32 26.7
ER
ve 16 13.3
+ve 104 86.7
PR
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expenses. Each section was ﬁrst scanned at low-power magni-
ﬁcation (·40) to select the most vascularized areas, three hot
spots were selected. A25-point chalkley eyepieces graticule
was applied to each hot spot and oriented to permit the max-
imum number of points to hit on or within the areas of high
lighted microvessel using ·200 magniﬁcation.
Achallay count for an individual tumor was taken as the
mean value of the three graticule counts.20
2.3. Determination of serum level of vascular endothelial growth
factor (VEGF)
Human vascular endothelial growth factor (Hub VEGF)
ELISA kit was used for in vitro quantitative analysis of human
serum and it was purchased from Biosource. Camarillo, Cali-
fornia USA.21
2.4. Immunohistochemistry
Four micrometer tissue sections were cut and placed on poly-
lysin-coated slides and immunohistochemically stained using
avindin–biotin complex immunoperoxidase technique.22 and
commercially available VEGF monoclonal anti-body. The
degree of reactivity with antibody was graded semi quantita-
tive analysis, positive tumor cells was expressed as the per-
centage of total number of cells, and assigned to one of
four categories: Negative (0) (less than 10%), focal (+)
(10–40%), variable ++ (40–70%), and uniform +++
more than (70%).
The speciﬁcity of immunohistochemical stains, in each case
was conﬁrmed by concomitant run with negative control.
2.5. Statistical analysis
Continuous parametric variable were reported as median and
range. The cut-off points used for categorization were based
on previously described cut-off points in the literature. Cate-
gorical variables were presented as frequency of observation
and/or percentage. Correlations between categorical variables
were done by Chi-square coefﬁcient.
The duration of follow-up was calculated from the date of
registration to the date of death or last follow-up. The relapse
free survival period measured as the interval between the end
of treatment and relapse or death or date of the last follow-
up evaluation in patients who had no relapse and was esti-
mated by Kaplan–Meier method. Overall survival period was
measured as the interval between the beginning of treatment
and death or date of the last follow up evaluation and was esti-
mated by Kaplan–Meier methods.
For identiﬁcation of factors that independently affecting
survival we used Cox proportional-hazard model. A minimum
signiﬁcance level of 0.05 on univariate analysis was used as cri-
terion for determining multivariate testing.
Statistical analysis was performed using SPSS 17, statistical
package (SPSS, Inc., Chicago, Illinios).ve 24 20.0
+ve 96 80.0
HER2
+ve 35 29.2
ve 85 70.83. Results
Table 1 showed the clinicopathological characteristics of 120
patients of non metastatic breast cancer.3.1. Correlation of serum VEGF with clinical factors
The mean serum level of VEGF in breast cancer patients be-
fore surgery was signiﬁcantly higher when either compared
to that in control group P= 0.001 or that in the same patient
after surgery. P= 0.001 (Table 2).
The data of the present study showed a signiﬁcant increase
in mean serum level of VEGF in patients with positive vascular
invasion and presence of distant metastasis P= 0.013 (Table 3,
Fig. 1). Correlation of serum VEGF and clinicopathological
parameters showed, serum VEGF was strongly associated with
grade III tumor, large tumor size more than 2 cm, positive
lymph node, negative hormone receptor status and +ve
HER2-neu (Table 4).
Table 2 VEGF (pg/ml) in control group and breast cancer
patients.
Control
group
no. (30)
Patient
before
surgery
no. (120)
Patients after
treatment
Range 45–280 33.0–2710.0 55–750
Mean 125.6 450.0 172.0
SD 52.9 108.6 103.0
Median 130.0 460.0 175.0
P1 0.001* 0.012*
P2 0.001*
Table 3 Relation between vascular invasion results, VEGF
and MVD.
Patients with
negative vascular
invasion
Patients with
positive vascular
invasion
P
VEGF
Range 33–1050.0 650–2710 0.013*
Mean 330.6 960.0
SD 205.2 805.6
MVD
Range 2.07–3.65 2.01–3.52 0.32
Mean 2.88 2.71
SD 0.65 0.55
Total number 96 24
Figure 1 A case of grade i inﬁltrating ductal carcinoma
showing a ﬁbrovascular stroma including numerous vessels
ranging from 5 to 7 vessels per high power ﬁeld having MVD of
3.6 (H&E)(A-·200 and B-·400).
Table 4 Illustrate clinicopathological characteristics of
patients with positive VEGF (40 patients).
+ve VEGF
Age
<50 20/78
>50 20/42
Menstrual status
Pre menopause 25/72
Post menopause 15/48
Tumor grade
II 14/80
III 26/40
Tumor size
T1 0/8
T2 30/96
T3 10/16
Lymphnode status
+ve 32/80
ve 8/40
FR status
+ve 16/16
ve 24/104
PR status
+ve 12/24
ve 18/96
HER2 neu
+ve 19/35
ve 21/85
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The minimum duration of follow up was 24 months and max-
imum duration 48 months calculated from the date of initia-
tion of therapy. Survival curves were done using cox
proportional hazard method. At the end of 4 years, the overall
survival of patients with VEGF level above the mean was 45%versus 65% for those having VEGF concentration below the
mean (Figs. 2 and 3).
In multivariate analysis, tumor size (P (0.001), tumor grade
P (0.0013), number of lymph node P (0.0001), and VEGF P
(0.13) were independent factors affecting overall and disease
free survival (Tables 5 and 6).
3.3. Tissue expression of vascular endothelial growth factor
There was a signiﬁcant association between histopathologic
grade and VEGF expression P (0.001).
The data of ELISA (serum VEGF) correlated with the re-
sults of immunohistochemical analysis where SVEGF levels
higher than median correlated strongly with uniform positive
tissue expression of VEGF and correlation was signiﬁcant
(Figs. 4 and 5).
4. Discussion
In breast cancer, intra tumoral microvessels density IMD is
now established as one of the standard prognostic factors for
predicting metastasis and relapse-free or overall survival. The
assessment of angiogenesis is also of potential relevance in
identifying these who may beneﬁt from anti angiogenic thera-
pies. IMD is assessed primarily by quantiﬁcation of MVD and
the techniques are laborious, require experience. The measure-
ment of circulating concentrations of speciﬁc angiogenic
factors such as VEGF may provide less subjective measure-
ment. In the present work, there was a signiﬁcant association
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Figure 2 Overall survival of patients with non metastatic breast
cancer.
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Figure 3 Disease free survival of patients with non metastatic
breast cancer.
Table 5 Showed different factors that affect overall survival
for 48 months.
Survive Die P
n= 85 n= 35
Age
<50 65 13 0.01*
>50 20 22
Menstrual status
Pre menopause 52 20 >0.05
Post menopause 33 15
Tumor size
T1 7 1 0.001*
T2 70 26
T3 8 8
Tumor type
Inﬁltrating duct carcinoma 78 30 >0.05
Inﬁltrating lobular carcinoma 7 5
Grade
I 11 1 0.0013*
II 60 8
III 14 26
Vascular invasion
Positive 3 21 0.001*
Negative 82 14
Number of L.N.
Negative 35 5 0.001*
1–3 22 6
>3 28 24
Stage
I 4 0 0.0025*
II 70 14
III 11 21
ER
ve 10 6 0.136
+ve 75 29
PR
ve 15 9 0.11
+ve 70 26
VEGF
Mean 420.0 920.0 0.013*
SD 102.6 465.2
MVD
Mean 2.64 2.45 >0.05
SD 0.98 1.02
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breast cancer than patients with benign breast lesions. Thus
raising the possibility of using this parameter in differentiating
between these two conditions.
Further more, a high serum VEGF concentration was sig-
niﬁcantly associated with high tumor grade and large tumor
size more than 2 cm in size. This is agreement with previous
study on breast cancer, and on lung cancer,23 where they found
that high expression of VEGF was not only associated with
larger tumors but also with larger metastatic deposits, likely
through the growth factor inducing a rich vascular network,
and a correspondingly more nutrition environment for tumor
growth. The current study also found that such tumors be-
haved more aggressively, as they were signiﬁcantly associated
with the presence of lymph nodes LN metastasis, distant
metastasis and poorer survival.These ﬁndings are similar to others, both in breast cancer
and other tumor types.24 we have also reported that low serum
VEGF level was strongly associated with low stage, negative
lymph-node status, and low grade tumor, ﬁndings that are
compatible with those of Martin et al.25 It has been reported
that serum VEGF level changes in parallel with treatment,
according to our results high serum VEGF concentrations
measured before treatment were found to be correlated with
high incidence of relapse, in this respect serum VEGF may
be superior to the more often used breast serum markers but
these ﬁndings need to be further investigated in a prospective
study.
Table 6 Illustrate different factors that affect disease free
survival for 48 months.
Free Survive Relapse or die P
n= 56 n= 64
Age
<50 36 42 >0.05
>50 20 22
Pre menopause 33 39 >0.05
Post menopause 23 25
Tumor size
T1 5 3
T2 49 47 >0.05
T3 2 14
Tumor type
Inﬁltrating duct carcinoma 48 60 >0.05
Inﬁltrating lobular carcinoma 8 4
Grade
I 8 4
II 42 26 0.022*
III 6 34
Vascular invasion
Positive 3 21 0.013*
Negative 53 43
Number of L.N.
Negative 32 8
1–3 16 12 0.001*
>3 8 44
Stage
I 3 1
II 50 34 0.013*
III 3 29
ER
ve 8 8 >0.05
+ve 48 56
PR
ve 10 14 >0.05
+ve 46 50
VEGF
Mean 325.0
SD 109.5 465.3 0.01*
MVD
Mean 2.65
SD 0.88 0.66 >0.05
Figure 4 Breast ductal carcinoma showing malignant ductal cells
(T), inﬁltrating part of the muscle (m), the tumor margins showing
multiple, dilated proliferating blood vessels (BV) (IHC-VEGF
·100).
Figure 5 GIII invasive ductal carcinoma (T) showing prominent
angiogenesis –multiple dilated proliferating congested blood
vessels (BV) (IHC-VEGF ·400).
222 E.M. Ali et al.We have found that patients with serum VEGF level above
the mean had an over all survival of 45% versus 65% for those
with SVEGF level below the mean.
These data are supported by publication concerning the
prognostic signiﬁcance of serum VEGF25 The 4 years over
all survival rates reported in the present work were 45% for
patients having their pretreatment SVEGF levels above the
mean, while those with serum VEGF levels below the mean
has 4 years over all survival rates 65%. In multivariate analysis
SVEGF expression emerged as a signiﬁcant parameter for
poorer overall survival and disease free survival indicating that
SVEGF is molecule particularly important for predicting
worse prognosis in conjunction with other prognostic factors.Observations that are supported by other studies25,26 in the
current study, our data identify that tissue VEGF which can be
detected in archival materials, and is signiﬁcantly associated
with serum VEGF might be a biologically and clinically useful
marker in diagnosing breast cancer and identifying high risk
group.
It should be noted that breast cancer patients with positive
vascular invasion have an elevated level of serum VEGF than
do patients with negative vascular invasion and this supported
by Altomaas et al.27 that may reﬂect the importance of VEGF
in vascular invasion. Since it play an important role in angio-
genesis. Meanwhile, the MVD in patients with positive vascu-
lar invasion was not signiﬁcantly different from patients with
negative vascular invasion. Axelsson et al.28 disagree with that
and reported that, the average MVD was signiﬁcantly higher
in patients with vascular invasion than in patients with no vas-
cular invasion. This can be attributed to the primitively meth-
od applied in the measurement of MVD in that study.
Elevated serum and tissue VEGF associated with poor outcome in breast cancer patients 223Overall, the clinical signiﬁcance of high microvessel density
in breast cancer remains uncertain, and the variability in tech-
nical approaches and difﬁculty in distinguishing blood and
lymphatic microvessels appears to contribute to this uncer-
tainty. Visual and image cytometric microvessel density count-
ing methods are each associated with key advantages and
limitations. For example, microscopic visual counting is less
expensive and much more widely available among patholo-
gists, but the inherent subjectivity of this method may limit in-
ter observer reproducibility. In contrast, image cytometry is
likely to be more objective and reproducible and can measure
vessel luminal area, vessel luminal perimeter and the number
of immunostained areas per microscopic ﬁeld or scanned area.
In the past few years, image cytometric microvessel area and
microvessel perimeter have been demonstrated as independent
prognostic factors in invasive ductal carcinoma.29–31
Goddard et al.29 using anti-factor VIII to assess angiogen-
esis, reported no signiﬁcant correlation between manual micro-
vessel counting and computer image analysis. The Chalkley
count technique seems to be preferable for estimating angio-
genesis with regard to the prognostic stratiﬁcation of breast
cancer patients, based on its strong prognostic impact, and
acceptable reproducibility.
In the present study, MVD measured by Chalkely method
ranged from 1.7 to 3.9 with a mean of (2.8±0.64) in breast can-
cer patients. Accordingly, as the tumor grade increased the
MVD value increases. (MVD of G1= 1.8, MVD of G2= 2.5
andMVD of G3= 3.6), these results are supported by a Chalk-
ley count for an individual tumor when taken as the mean value
of the three graticule count which resulted in that MVD ranged
from 1.0 to 7.6 with a mean of (2.557±0.09).
5. Conclusion
It appears from this study of human breast cancer that, as has
been reported by in vitro studies, VEGF plays a role in angio-
genesis. It also appear that breast cancers which express high
levels of VEGF characterized by greater angiogenesis and
lymphangiogenesis and are associated with the presence of
both LN and distant metastasis. Such tumor behaves more
aggressively as indicated by the associations with shorter dis-
ease free and overall survival. VEGF appear to play an impor-
tant role in progression of breast carcinoma and to have a
signiﬁcant impact on patient prognosis and can be used to
identify a subset of breast cancer at higher risk for develop-
ment of recurrence and distant metastasis.References
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